This trial will test the effectiveness of a new medication, KarXT, for people with schizophrenia who haven't responded well to other treatments. The study will last 6 weeks and will compare KarXT to a placebo. The primary objective is to measure the effect of KarXT on symptoms of schizophrenia using the PANSS scale.
1 Primary · 6 Secondary · Reporting Duration: Week 6
400 Total Participants · 2 Treatment Groups
Primary Treatment: Xanomeline and Trospium Chloride Capsules · Has Placebo Group · Phase 3
Age 18 - 55 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: